Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Oral Ixazomib in Relapsed/Refractory Follicular Lymphoma
2013-002302-32Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall response rate. Started Aug 2013; status: completed.
02
Drugs
ixazomib
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-002302-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002302-32.